MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10875-023-01607-3

Медицинская библиотека · Journal of clinical immunology · 2024

Clinical and Treatment History of Patients with Partial DiGeorge Syndrome and Autoimmune Cytopenia at Multiple Centers.

Patel Priya K, Chinga Michell Lozano, Yilmaz Melis, Joychan Sonia, Ujhazi Boglarka, Ellison Maryssa, Gordon Sumai, Nieves Daime, Csomos Krisztian, Eslin Don, Afify Zeinab A, Meznarich Jessica, Bohnsack John, Walkovich Kelly, Seidel Markus G, Sharapova Svetlana, Boyarchyk Oksana, Latysheva Elena, Tuzankina Irina, Shaker Ahmad B, Ayala Irmel, Sriaroon Panida, Westermann-Clark Emma, Walter Jolan E

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients with partial DiGeorge syndrome (pDGS) can present with immune dysregulation, the most common being autoimmune cytopenia (AIC). There is a lack of consensus on the approach to type, combination, and timing of therapies for AIC in pDGS. Recognition of immune dysregulation early in pDGS clinical course may help individualize treatment and prevent adverse outcomes from chronic immune dysregulation.

OBJECTIVES

Objectives of this study were to characterize the natural history, immune phenotype, and biomarkers in pDGS with AIC.

METHODS

Data on clinical presentation, disease severity, immunological phenotype, treatment selection, and response for patients with pDGS with AIC were collected via retrospective chart review. Flow cytometric analysis was done to assess T and B cell subsets, including biomarkers of immune dysregulation.

RESULTS

Twenty-nine patients with the diagnosis of pDGS and AIC were identified from 5 international institutions. Nineteen (62%) patients developed Evan's syndrome (ES) during their clinical course and twenty (69%) had antibody deficiency syndrome. These patients demonstrated expansion in T follicular helper cells, CD19hiCD21lo B cells, and double negative cells and reduction in CD4 naïve T cells and regulatory T cells. First-line treatment for 17/29 (59%) included corticosteroids and/or high-dose immunoglobulin replacement therapy. Other overlapping therapies included eltrombopag, rituximab, and T cell immunomodulators.

CONCLUSIONS

AIC in pDGS is often refractory to conventional AIC treatment paradigms. Biomarkers may have utility for correlation with disease state and potentially even response to therapy. Immunomodulating therapies could be initiated early based on early immune phenotyping and biomarkers before the disease develops or significantly worsens.

Для цитирования: Patel Priya K, Chinga Michell Lozano, Yilmaz Melis, Joychan Sonia, Ujhazi Boglarka, Ellison Maryssa, Gordon Sumai, Nieves Daime, Csomos Krisztian, Eslin Don, Afify Zeinab A, Meznarich Jessica, Bohnsack John, Walkovich Kelly, Seidel Markus G, Sharapova Svetlana, Boyarchyk Oksana, Latysheva Elena, Tuzankina Irina, Shaker Ahmad B, Ayala Irmel, Sriaroon Panida, Westermann-Clark Emma, Walter Jolan E. Clinical and Treatment History of Patients with Partial DiGeorge Syndrome and Autoimmune Cytopenia at Multiple Centers.. Journal of clinical immunology. 2024. DOI: 10.1007/s10875-023-01607-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.